Kidney Cancer Weekly

May 11, 2026

Videos

Peer-to-Peer Clinical Conversations

KIM-1 Biomarker Analysis in the CAN-I Trial for Non-Clear Cell RCC - Wenxin Xu

Wenxin Xu

Wenxin (Vincent) Xu reviews KIM-1 biomarker data from the CAN-I trial, a phase 2 study of cabozantinib, ipilimumab, and nivolumab in non-clear cell renal cell carcinoma.

View

Diagnostic Imaging and Treatment Options for Small Renal Masses - Fernando Pablo Secin

Fernando Secin

Zachary Klaassen hosts Fernando Secin to discuss the management of small renal masses.

View

Beyond the Abstracts

Diagnostic Practice and Awareness of SDH- and FH-Deficient Renal Cell Carcinoma: Results from an Italian Study Group of Uropathology (GIUP) Survey - Beyond the Abstract

Response Assessment of Patients with Locally Advanced Renal Cell Carcinoma Receiving Prior Systemic Therapy - Beyond the Abstract

Conference Coverage

SES AUA 2026: Assessing the Role of Girentuximab PET/CT in Clinical Decision-Making: Results from a National Survey of Urologic Oncologists

SES AUA 2026: Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC

EAU 2026: [89Zr]Zr-girentuximab PET/CT in the Non-invasive Characterization of Indeterminate Renal Lesions: Initial Real-world Clinical Experience

ASCO GU 2026: Adjuvant Pembrolizumab in Non-Clear Cell RCC After Nephrectomy: An International Multicenter Study

ASCO GU 2026: Geographic Disparities in the Availability of RCC Clinical Trials in the US

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Association Between Polymorphisms in Genes Encoding PD-1/PD-L1 Molecules and Clinicopathological Features in Clear Cell Renal Cell Carcinoma.

Urinary microbiota diversity and composition in patients with advanced renal cell cancer.

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma.

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Early Biohumoral Detection of Acute Kidney Injury After Robotic Renal Surgery and Its Impact on Medium-Term Renal Function.

Ablation and Surgery Show Comparable Long-term Outcomes for T1a Renal Cell Carcinoma: A Danish Nationwide Registry Study - Beyond the Abstract

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

Agreement of Axial T2-MRI Versus Contrast-Enhanced CT for Solid Renal Mass Active Surveillance - Beyond the Abstract

Predictors for Recurrences Within One Year Following Radical Nephrectomy for Non-metastatic Renal Cell Carcinomas.

Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login